Document Type : Original article
Authors
1
Department of Clinical Biochemistry, Iranshahr University of Medical Sciences, Iranshahr, Iran
2
Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
3
Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Canada
4
) Genetics of Non-communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
5
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Abstract
This meta-analysis aimed to provide an up-to-date comprehensive evaluation on the association between the MDM2 40bp indel polymorphism and cancer susceptibility. Eligible studies were retrieved by searching Web of Science, PubMed, Scopus, and Google scholar databases up to August 27, 2018. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of association between the polymorphism and cancer risk. The findings of this meta-analysis revealed that the 40bp indel polymorphism significantly increased the risk of overall cancer risk in heterozygous (OR=1.06, 95%CI=1.01-1.11, P=0.016) and ID+DD (OR=1.07, 95%CI=1.01-1.14, P=0.027) genotypes. Stratified analysis by cancer type proposed that the study indel variant significantly associated with the risk of gastrointestinal cancer in heterozygous (OR=1.18, 95%CI=1.06-1.32, P=0.003) and ID+DD (OR=1.18, 95%CI=1.06-1.30, P=0.002) genotypes. The present findings showed a significant association between the MDM2 40bp indel polymorphism and overall cancer risk as well as gastrointestinal cancer susceptibility. Larger and well-designed researches are required to validate the findings association in detail.
Keywords
)